- Home
- GPUS vs SLXN Comparison
GPUS vs SLXN Comparison
Compare GPUS & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPUS
- SLXN
- Stock Information
- Founded
- GPUS 1969
- SLXN 2008
- Country
- GPUS United States
- SLXN Israel
- Employees
- GPUS N/A
- SLXN N/A
- Industry
- GPUS
- SLXN
- Sector
- GPUS
- SLXN
- Exchange
- GPUS NYSE
- SLXN NYSE
- Market Cap
- GPUS 4.1M
- SLXN 6.9M
- IPO Year
- GPUS 1996
- SLXN N/A
- Fundamental
- Price
- GPUS $2.25
- SLXN $0.75
- Analyst Decision
- GPUS
- SLXN Strong Buy
- Analyst Count
- GPUS 0
- SLXN 1
- Target Price
- GPUS N/A
- SLXN $5.00
- AVG Volume (30 Days)
- GPUS 50.9K
- SLXN 218.8K
- Earning Date
- GPUS 05-19-2025
- SLXN 05-21-2025
- Dividend Yield
- GPUS N/A
- SLXN N/A
- EPS Growth
- GPUS N/A
- SLXN N/A
- EPS
- GPUS N/A
- SLXN N/A
- Revenue
- GPUS $106,662,000.00
- SLXN N/A
- Revenue This Year
- GPUS N/A
- SLXN N/A
- Revenue Next Year
- GPUS N/A
- SLXN N/A
- P/E Ratio
- GPUS N/A
- SLXN N/A
- Revenue Growth
- GPUS 3.50
- SLXN N/A
- 52 Week Low
- GPUS $2.14
- SLXN $0.21
- 52 Week High
- GPUS $20.30
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- GPUS N/A
- SLXN N/A
- Support Level
- GPUS N/A
- SLXN N/A
- Resistance Level
- GPUS N/A
- SLXN N/A
- Average True Range (ATR)
- GPUS 0.00
- SLXN 0.00
- MACD
- GPUS 0.00
- SLXN 0.00
- Stochastic Oscillator
- GPUS 0.00
- SLXN 0.00
About GPUS HYPERSCALE DATA INC
Hyperscale Data Inc, formerly Ault Alliance Inc is a diversified holding company. It operates a data center at which it mines Bitcoin and provides mission-critical products that support a diverse range of industries, including oil exploration, crane services, defense/aerospace, industrial, automotive, medical/biopharma, consumer electronics, hotel operations and textiles. The company has eight reportable segments: Energy and Infrastructure; Technology and Finance; SMC; Sentinum, Inc.; GIGA; TurnOnGreen; ROI; and Ault Disruptive.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.